Browse by Research Team

2007

The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk.
Schuster, H.
Expert Review of Cardiovascular Therapy 5 (2): 177-193. March 2007

2006

Rosuvastatin may be more effective than atorvastatin in African-Americans with hypercholesterolemia.
Fonseca, F.A., Izar, M.C., Silva, M.A., Karapanos, A., Schuster, H. and Singh, D.
Evidence-Based Cardiovascular Medicine 10 : 96-100. June 2006

Does rosuvastatin improve lipid levels in patients with the metabolic syndrome more effectively than atorvastatin?
Schuster, H.
Nature Clinical Practice Cardiovascular Medicine 3 : 74-75. February 2006

2005

Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population.
Fagerberg, B., Edwards, S., Halmos, T., Lopatynski, J., Schuster, H., Stender, S., Stoa-Birketvedt, G., Tonstad, S., Halldorsdottir, S. and Gause-Nilsson, I.
Diabetologia 48 : 1716-1725. 7 July 2005

Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Stender, S., Schuster, H., Barter, P., Watkins, C. and Kallend, D.
Diabetes Obesity and Metabolism 7 : 430-438. 1 January 2005

Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
Cheung, R.C., Morrell, J.M., Kallend, D., Watkins, C. and Schuster, H.
International Journal of Cardiology 100 : 309-316. 1 January 2005